Abstract
Background: Hepatotoxicity is the gravest concern associated with use of anti-tuberculous drugs. The objective of this study was to evaluate the individual and combined hepatoprotective effect of silymarin and cholecalciferol in isoniazid induced hepatotoxicity. Methods: This animal experimental study was conducted at the Department of Pharmacology & Therapeutics, and Multidisciplinary Research Laboratory, Islamic International Medical College, in collaboration with National Institute of Health, Islamabad, Pakistan. Fifty adult Balb-C mice were included in this study. They were distributed into 5 groups. Each group contained 10 mice. Group 1 was normal control, Group 2 disease control, and Group 3, 4, and 5 were experimental groups. Except Group 1, all other groups were given isoniazid (150 mg/Kg) and only Group 2 was not fed with any drugs. Group 3 received silymarin (50 mg/Kg dissolved in physiological saline) through intragastric gavage for 28 days. Group 4 was given Vitamin D (1,000 IU/Kg) for 28 days. Group 5 was given isoniazid (150 mg/Kg) along with silymarin and Vitamin D for 28 days. Serum ALT and bilirubin levels were estimated on day 0, 14, and 28. Results: As compared to Group 2, Group 3 to Group 5 showed a lower rise in serum ALT and bilirubin (p<0.001). Group 4 and 5 showed significantly reduced biochemical markers (ALT and bilirubin) (p=0.001). Conclusion: Silymarin and cholecalciferol effectively and synergistically ameliorate hepatotoxicity induced by isoniazid. Silymarin offers better hepatoprotection than cholecalciferol in isoniazid induced hepatotoxicity. Pak J Physiol 2024;20(1):37-40
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
